SCHEMBL27409003

SCHEMBL27409003

COc1ccc(-c2ncco2)nc1N

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA1 P30542 3/20 0.35
▸ ADORA2A P29274 3/20 0.35
▸ TLR7 Q9NYK1 1/20 0.35
▸ ADORA2B P29275 1/20 0.35
▸ TUBB4A P04350 2/20 0.35
▸ TUBB P07437 2/20 0.35
▸ TUBA3C P0DPH7 2/20 0.35
▸ TUBA1B P68363 2/20 0.35
▸ TUBA4A P68366 2/20 0.35
▸ TUBB4B P68371 2/20 0.35
▸ TUBB3 Q13509 2/20 0.35
▸ TUBB2A Q13885 2/20 0.35
▸ TUBB8 Q3ZCM7 2/20 0.35
▸ TUBA3E Q6PEY2 2/20 0.35
▸ TUBA1A Q71U36 2/20 0.35
▸ TUBA1C Q9BQE3 2/20 0.35
▸ TUBB6 Q9BUF5 2/20 0.35
▸ TUBB2B Q9BVA1 2/20 0.35
▸ TUBB1 Q9H4B7 2/20 0.35
▸ TLR8 Q9NR97 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27408994 0.83 KDM4E (0.39) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL27408993 0.79 MAPT (0.39) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL14031549 0.73 PDPK1 (0.40) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL28207466 0.72 ALDH1A1 (0.44) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL15649891 0.72 CFTR (0.37) ADORA1TLR7TUBB4ATUBBTUBA3C
SCHEMBL21801560 0.71 HSP90AA1 (0.50) ADORA2AKDM4EALDH1A1RAB9AGSK3B
SCHEMBL16741126 0.71 TPH1 (0.40) ADORA2AADORA2BCCNCCDK8GSK3B
SCHEMBL26260076 0.70 HIF1A (0.41) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL14546840 0.70 ADORA2A (0.37) ADORA2AADORA2BTUBB4ATUBBTUBA3C
SCHEMBL3788892 0.70 CLK1 (0.36) ADORA1TLR7ALDH1A1CCNCCDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260108527-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS INC (US) 2026-04-23 — — US disclosed
EP-4598912-A1 POLO LIKE KINASE 4 INHIBITORS Oric Pharmaceuticals, Inc. (US) 2025-08-13 — — EP disclosed
WO-2024076891-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. (US) 2024-04-11 — — WO disclosed
WO-2024076891-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. (US) 2024-04-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260108527-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 ADORA1 1629/4885ADORA2A 1997/4885TLR7 3851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback